Author pages are created from data sourced from our academic publisher partnerships and public sources.
Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy.
- G. Papatheodoridis, H. Chan, B. Hansen, H. Janssen, P. Lampertico
- Journal of hepatology
- 1 April 2015
In the treatment of chronic hepatitis B (CHB), the ultimate goal is preventing hepatitis B virus (HBV)-associated liver disease, including hepatocellular carcinoma (HCC). Recently published studies… Expand
PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy.
BACKGROUND & AIMS Risk scores for hepatocellular carcinoma (HCC) developed in Asians offer poor-moderate predictability in Caucasian patients with chronic hepatitis B (CHB). This nine center cohort… Expand
Discontinuation of oral antivirals in chronic hepatitis B: A systematic review
The possibility of safe discontinuation of therapy with nucleos(t)ide analogues (NAs) remains one of the most controversial topics in the management of chronic hepatitis B. Therefore, we… Expand
Outcome of hepatitis B e antigen–negative chronic hepatitis B on long‐term nucleos(t)ide analog therapy starting with lamivudine
We determined the clinical outcome of hepatitis e antigen (HBeAg)‐negative chronic hepatitis B patients treated with long‐term nucleos(t)ide analog therapy starting with lamivudine. We evaluated 201… Expand
Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine…
Objective To evaluate the risk and predictors of hepatocellular carcinoma (HCC) in HBeAg-negative chronic hepatitis B patients of the large HEPNET.Greece cohort study who received long-term oral… Expand
Adipokines in Nonalcoholic Steatohepatitis: From Pathogenesis to Implications in Diagnosis and Therapy
Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome and can vary from benign steatosis to end-stage liver disease. The pathogenesis of non-alcoholic… Expand
Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: A meta-analysis.
- C. Katsagoni, M. Georgoulis, G. Papatheodoridis, D. Panagiotakos, M. D. Kontogianni
- Metabolism: clinical and experimental
- 1 March 2017
BACKGROUND/OBJECTIVES Although lifestyle modifications remain the cornerstone therapy for non-alcoholic fatty liver disease (NAFLD), the optimal lifestyle intervention is still controversial. The aim… Expand
Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir.
- G. Papatheodoridis, G. Dalekos, +17 authors P. Lampertico
- Journal of hepatology
- 1 February 2015
BACKGROUND & AIMS The risk of hepatocellular carcinoma (HCC) in Caucasian patients with chronic hepatitis B (CHB), treated with entecavir (ETV) or tenofovir (TDF), is unclear. We evaluated the… Expand
Immunological Characteristics of Colitis Associated with Anti-CTLA-4 Antibody Therapy
ABSTRACT Anti-CTL4-A therapy is associated with development of colitis. We characterized ipilimumab-associated colitis in nine melanoma patients (6 male, mean age: 55.3-yrs). Median value for… Expand
Course of virologic breakthroughs under long‐term lamivudine in HBeAg‐negative precore mutant HBV liver disease
- G. Papatheodoridis, E. Dimou, A. Laras, V. Papadimitropoulos, S. Hadziyannis
- 1 July 2002
We studied the course of virologic breakthroughs detected by a quantitative polymerase chain reaction (PCR) assay in 32 of 78 patients with hepatitis B e antigen (HBeAg)‐negative precore mutant… Expand